MarginsXMarginsX
Home › Markets › Health Care › IMRX

Immuneering Corporation (IMRX)

IMRX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$3.52
-5.12% on the day
Market cap
$228.0M
Micro cap
Revenue · 2023
$0
-100.0% on 2022
Net income · 2023
-$53.5M

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2023-12-31, https://www.sec.gov/Archives/edgar/data/1790340/000179034024000024/0001790340-24-000024-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2023-12-31.

Profile

FieldValue
TickerIMRX on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2021
SEC CIK0001790340
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2023

LineValue
Revenue$0
Net income-$53.5M
Operating income-$58.4M
Net marginNeeds revenue and net income
Operating marginOperating income not reported
Revenue growth-100.0%
Cash$59.4M
Total assets$102.6M
P/E (computed)Net income was not positive
P/S (computed)Needs market cap and revenue

Warning signs

Cash runway
11.4 months
$58.2M cash at September 30, 2026
Share count, 1 year
+0.3%
2025-10-31 to 2026-10-31
Going-concern doubt
No
10-Q filed October 29, 2026
Insider net buying, 12 months
$334K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.
"Management considered whether or not there are conditions or events, in the aggregate, that raise substantial doubt about the entity's ability to continue as a going concern, and concluded that there are none as it estimates that its cash, cash equivalents and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements for at least 12 months from the issuance date of t"
10-Q 2026-10-29
Cash and burn$58.2M cash; operating cash flow -$15.4M a quarter.Report 2026-09-30
Shares outstanding64,763,155 (2026-10-31); 64,569,967 a year earlier.Cover page 2026-10-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorRSM US LLP, Boston, Massachusetts, United StatesPCAOB Form AP 2026-03-13
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $334K, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$24.2M-$16.8M$58.2MNo debt tagsNeeds four quarters10-Q 2026-10-29
Q2 2026
2026-06-30
Not filed-$17.3M-$16.5M$41.3MNo debt tagsNeeds four quarters10-Q 2026-10-29
Q1 2026
2026-03-31
Not filed-$13.5M-$18.4M$47.3MNo debt tagsNeeds four quarters10-Q 2026-10-29
Q4 2025
2025-12-31
Not filed-$11.6M-$9.8M$128.6MNo debt tagsNeeds four quarters10-K 2026-03-06
Q3 2025
2025-09-30
Not filed-$15.0M-$12.0M$227.6MNo debt tagsNeeds four quarters10-Q 2026-10-29
Q2 2025
2025-06-30
Not filed-$14.4M-$9.4M$26.4MNo debt tagsNeeds four quarters10-Q 2026-10-29
Q1 2025
2025-03-31
Not filed-$15.0M-$14.1M$35.9MNo debt tagsNeeds four quarters10-Q 2026-10-29
Q4 2024
2024-12-31
Not filed-$18.1M-$14.5M$36.1MNo debt tagsNeeds four quarters10-K 2026-03-06

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52025-09-25
Latest annual report10-K2026-03-06
Latest quarterly / interim10-Q2026-10-29
Latest current report8-K2026-11-09
Latest proxyDEFA14A2026-04-20

Source: SEC EDGAR submissions feed, 326 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+0.8%
1 month+4.2%
3 months-28.7%
Year to date-43.6%
1 year-42.5%
From 52-week high-55.5%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
VNDAVanda Pharmaceuticals Inc.$3.81-4.51%$230.4M
BCYCBicycle Therapeutics plc$3.18-5.64%$222.9M
AMRNAmarin Corporation plc$11.31-0.62%$233.4M
DRUGBright Minds Biosciences Inc.$22.61-2.16%$222.0M
ARCTArcturus Therapeutics Holdings Inc.$8.31-0.60%$239.5M
FTHFaeth Therapeutics Inc.$9.28-7.48%$239.8M
BIOABioAge Labs Inc.$5.22-5.95%$239.9M
RCKTRocket Pharmaceuticals Inc.$2.16-6.09%$241.2M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier